CCG Wealth Management LLC Takes Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

CCG Wealth Management LLC acquired a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) during the 4th quarter, Holdings Channel.com reports. The firm acquired 150,000 shares of the company’s stock, valued at approximately $4,068,000. Structure Therapeutics accounts for about 2.3% of CCG Wealth Management LLC’s investment portfolio, making the stock its 10th largest holding.

A number of other hedge funds also recently added to or reduced their stakes in the stock. GAMMA Investing LLC increased its stake in Structure Therapeutics by 4,155.6% in the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after purchasing an additional 1,122 shares in the last quarter. FNY Investment Advisers LLC purchased a new position in Structure Therapeutics in the 4th quarter worth about $40,000. Assetmark Inc. increased its stake in Structure Therapeutics by 120.0% in the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after purchasing an additional 719 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Structure Therapeutics by 60.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after purchasing an additional 1,420 shares in the last quarter. Finally, Dearborn Partners LLC purchased a new position in Structure Therapeutics in the 3rd quarter worth about $202,000. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Price Performance

Structure Therapeutics stock opened at $29.97 on Monday. The business’s fifty day moving average is $29.65 and its two-hundred day moving average is $35.20. Structure Therapeutics Inc. has a 52 week low of $23.50 and a 52 week high of $62.74.

Wall Street Analyst Weigh In

GPCR has been the subject of a number of research reports. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective for the company. JMP Securities restated a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, HC Wainwright restated a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a research report on Thursday, December 19th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.